QuellTX
Marco Romano has extensive work experience in the field of research and scientific development. Marco is currently employed as a Senior Scientist at Quell Therapeutics since January 2022. Before joining Quell Therapeutics, Marco worked at King's College London as a Research Associate from May 2017 to February 2019 and again from March 2019 to January 2022.
Marco Romano began their education in 2004 at the Università del Salento, where they obtained a Bachelor's degree in Biotecnologie in 2009. Marco then pursued further studies at Alma Mater Studiorum – Università di Bologna and earned a Master's degree in Medical Biotechnology from 2008 to 2011. Continuing their education at the same institution, Marco received a Doctor of Philosophy (PhD) degree in Biomedical Science from 2012 to 2014.
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.